Test envafolimab with chemoradiation for advanced nasopharyngeal cancer
Part of Cancer, Ear, nose & throat clinical trials.
This trial studies whether adding envafolimab (an immune medicine) to standard chemo and radiation works better for people with locally advanced, untreated nasopharyngeal cancer. It may help the immune system attack the cancer while treatment shrinks it.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have nasopharyngeal cancer that is non-keratinizing (WHO type II or III), confirmed by biopsy
- Your cancer is stage III to IVA and has not been treated with radiation or chemotherapy yet
- Your overall health status is good (ECOG 0 to 1)
- Your blood tests are strong enough: hemoglobin, platelets, and white blood cells meet the trial cutoffs
- Your liver and kidney tests are within acceptable limits (and no severe heart/lung/kidney/bone marrow problems)
- You have not had certain prior treatments or immune medicines (especially prior PD-1/PD-L1 or CTLA-4 drugs)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two immune-based drugs (sintilimab and bevacizumab) plus standard chemotherapy for people with high-risk, locally advanced nasopharyngeal cancer that has spread to lymph nodes. The goal is to see if this approach works better than current treatments.
This trial tests a new immunotherapy drug (serplulimab) given together with standard chemotherapy and radiation for nasopharyngeal cancer that has spread to nearby lymph nodes. It aims to see if adding this drug can help shrink tumors and improve outcomes.
This trial tests if adding an immunotherapy drug (PD-1 inhibitor) after standard induction chemotherapy helps keep advanced nasopharyngeal cancer from coming back. It is for people who have completed 3 cycles of GP chemotherapy combined with a PD-1 inhibitor and have not had their cancer progress.
This trial tests a combination of two types of radiation therapy (standard SBRT and low-dose radiation) along with chemotherapy and an immunotherapy drug (PD-1 antibody) for people whose nasopharyngeal cancer has come back or spread. The goal is to see if this combination can better control the cancer.
This trial studies whether adding a PD-1 antibody (an immunotherapy) to standard chemoradiation can better control recurrent nasopharyngeal cancer that can’t be removed with surgery. If you qualify, you’d receive the study treatment and be closely monitored for side effects and cancer response.
This trial studies whether adding an anti–PD-1 immunotherapy to standard chemoradiotherapy can control nasopharyngeal cancer that has come back in the local area. It may help patients live longer or have the cancer respond better compared with chemoradiotherapy alone.
Hear when a new Locally Advanced Nasopharyngeal Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.